Introduction: Both cardiovascular disease and osteoporosis are important causes of morbidity and mortality in the elderly. The co-occurrence of cardiovascular disease and osteoporosis prompted us to review the evidence of an association between cardiovascular (CV) disease and osteoporosis and potential shared common pathophysiological mechanisms. Methods: A systematic literature search (Medline, Pubmed and Embase) was conducted to identify all clinical studies that investigated the association between cardiovascular disease and osteoporosis. Relevant studies were screened for quality according to guidelines as proposed by the Dutch Cochrane Centre and evidence was summarized.
Introduction
Cardiovascular (CV) disease and osteoporosis are both important causes of morbidity and mortality in aging men and women. They share common risk factors, such as increased age and inactivity, and are frequently found in the same individuals, suggesting a possible relationship. Results from epidemiological studies indicate an association between CV disease and osteoporosis. Prevalent CV disease and subclinical atherosclerosis have been found to be related to low bone mass and increased fracture risk [1] [2] [3] [4] . Similarly, low bone mineral density (BMD) has been related to increased cardiovascular risk [5] [6] [7] [8] . This relationship is often regarded as a result of aging; however, recent evidence suggests a direct association, independent of age and traditional cardiovascular risk factors and accumulating evidence from experimental research indicates a shared pathogenesis. A variety of factors that influence bone metabolism are involved in the development of vascular disease, for example, atherosclerosis and vascular calcification. Interestingly, several bone-related proteins are implicated in the calcification process resulting in mineral deposition [9] . This is important as calcification of the arterial wall may be a marker for CV disease and was shown to predict CV events [10] . Given the importance of identifying a person at risk for CV events or fractures, evidence for an association of CV disease with osteoporosis might have implications for screening decisions in patients with low bone mass and vice versa. This review aims to summarize all the present clinical literature about the association between CV disease and osteoporosis and to describe common pathophysiological mechanisms. The results of this review are grouped into two topics: clinical results, discussing the relationship between 1) cardiovascular disease and osteoporosis and 2) vice versa. In addition, the possible pathophysiological links of CV disease and osteoporosis will be discussed.
Materials and methods

Search strategy
A systematic search (in Medline, Pubmed and Embase) was conducted to identify all clinical studies from 1966 to January 2010 (last updated 8 June 2010) that investigated the association between cardiovascular disease and osteoporosis. The following search terms for cardiovascular disease were used: cardiovascular diseases, cerebrovascular diseases and peripheral vascular diseases. These searches were each combined with an osteoporosis search block and duplicates were removed. Searches were limited to human studies in the English, Dutch and German languages. The complete Medline search is available in Additional file 1. In addition, references from the retrieved articles were scanned for additional relevant studies.
Selection criteria
Abstracts were screened by one reviewer (DdU) and studies were included in the review if they fulfilled the following inclusion criteria: epidemiological studies (including prospective, cross-sectional, case-control, or retrospective studies) reporting the association between CV disease and osteoporosis in the general population or in patients with prevalent CV disease or low bone mass. Cardiovascular disease was defined as coronary heart disease (CHD) (myocardial infarction, angina pectoris, coronary insufficiency or ischemic heart disease), cerebrovascular disease (stroke, transient ischemic attacks), peripheral arterial disease (PAD) (lower extremity claudication, arterial thrombosis/ embolism, ankle brachial index (ABI) <0.90) or subclinical atherosclerosis measured as intima media thickness (IMT) or vascular calcification. In addition, bone mass had to be assessed as bone mineral density or bone quality, and osteoporosis was defined as low bone mass (T-score ≤-2.5) or increased fracture risk (vertebral and non-vertebral). Exclusion criteria were: reviews, letters, case-reports, intervention studies and biomechanical studies. Studies in patients with co-morbidity other than osteoporosis or CV disease were also excluded. Finally, investigations using risk factors of CV disease or osteoporosis as outcome measurements, such as hypertension, metabolic syndrome, atrial fibrillation, bone markers, and calcium supplementation were not included.
Assessment of study quality
The quality of each manuscript was systematically assessed with a checklist for cohort studies as proposed by the Dutch Cochrane Collaboration [11] (Additional file 2). Quality assessment included a scoring of the following components: definition of study population, the likelihood of bias, adequate blinding, the accuracy of outcome measurements, duration of follow-up and selective loss-to follow-up, the appropriateness of the statistical analysis and the clinical relevance. All items had the following answer options: yes/no/too little information to answer the question. We considered incomplete information or data important criteria for study quality. Therefore, if the answer could not be given because the study provided too little information, a negative score (for example, "no") was given. Each "no" was scored and an equal weight was given to each item. A maximum of 10 points could be given. The scores of each study are given in Tables 1 and 2 .
Statistical analysis
A formal meta-analysis of the prospective studies investigating the association between bone mass and risk for cardiovascular events and mortality was not possible due to extended heterogeneity between studies with respect to the study population and methods used. Furthermore, the number of prospective studies that were eligible for pooling was too small for analysis. For this reason, narrative summaries are provided in the results section and quantitatively presented in Tables 1  and 2 . The heterogeneity between studies in terms of study population and outcome measures is shown in Tables 1 and 2 . Moreover, cross-sectional studies are shown in Table 3 . studies about the inverse relationship. Figure 1 shows the flow-chart of included and excluded studies.
Study results
The relationship between CV disease and osteoporosis Cardiovascular disease and fracture risk Seven population-based cohort studies assessed the relationship between CV disease and fracture risk [1, 2, 4, [12] [13] [14] [15] ( Table 1 ). An increased risk of incident fractures was observed in four studies with risk rates ranging from 1.2 to 6.7 [1, 2, 13, 14] . The largest study included more than 30,000 twins with a follow-up duration of 20 years [13] . In this study, twins, without prevalent CV disease, were included at the age of 50 years and followed up until a first hip fracture, death or end of follow-up period. Twins were considered unexposed until the first CV event. An increased hip fracture risk was found after all diagnoses of CV disease in both men (hazard ratio (HR) 6.65; 95% CI 4.82 to 9.19) and women (HR 4.42; 95% CI 3.49 to 5.61).
Furthermore, this study showed that CHD was associated with an increased fracture risk (HR 2.32; 95% CI 1.91 to 2.84) as was cerebral vascular disease (HR 5.09 95% CI 4.18 to 6.20) [13] . This was confirmed in a large population case-control study. This case-control study was conducted using the Dutch PHARMO Record Linkage System database. Patients (n = 6,763) with a hip fracture were compared with age-and sex-matched patients without a hip fracture (n = 26,341), with the objective to evaluate the association between stroke and risk of hip fracture [16] . The prevalence of stroke was 3.3% in cases versus 1.5% in control patients. The risk for a hip fracture was increased in patients who experienced a stroke before the index date (OR 1.96; 95% CI 1.65 to 2.33).
Three studies looked at the association between PAD and fracture risk. PAD was associated with increased risk for non-vertebral fractures (HR 1.47; 95% CI 1.07 to 2.04) [2] and hip fractures (HR 3.20; 95% CI 2.28 to 4.50) [13] . In contrast, a smaller study in men and women, with shorter follow-up time, did not find an association between PAD and non-vertebral fracture risk [15] . Time of follow-up might be an important factor explaining different results, for the risk of fractures den
was highest more than 10 years after the diagnosis of PAD [13] . Longitudinal analysis in healthy postmenopausal women (n = 2,262) showed that aortic calcifications (AC) represented a strong predictor for fragility fractures: AC predicted a 2.3-fold increased risk for hip fracture [1] . Not only women, but also men with advanced AC have a two-to three-fold increased fracture risk [14] . However, a large population-based study with 21 years follow-up, found no evidence that severity of vascular calcification, measured as AC, is associated with an increased risk of incident hip fracture [12] . Conflicting results might be due to differences in population and methodology. The incident fracture rates were equal in comparison to the other studies.
Hence, although heterogeneity makes it difficult to draw firm conclusions, there is evidence that subjects with atherosclerotic disease are at an increased risk for frailty fractures. There are insufficient data to draw conclusions about fracture risk in patients with prevalent coronary or cerebral CV disease. Cardiovascular disease and bone loss Longitudinal data about CV disease and bone loss were available from six studies [1] [2] [3] [4] 15, 17] . All studies showed that prevalent CV disease was associated with an increased bone loss during follow-up, independent of age and traditional risk factors. In addition, several cross-sectional studies similarly reported that prevalent CV disease is associated with low BMD [18] [19] [20] [21] [22] . In the next section the results are presented per subcategory of CV disease.
The association of CHD and BMD was only addressed in cross-sectional studies and all but one found an association with low BMD [20, [22] [23] [24] [25] . Several studies reported increased bone loss after an incident stroke. Particularly patients who are wheelchair-bound or have paretic limbs as a result of the stroke have significant bone loss within months after the stroke [26] . These studies were not included in this review, for the underlying pathogenesis is obvious. One study looked at bone density immediately after the stroke and found that female stroke patients have lower BMD than controls [27] . Since the BMD measurement was assessed within six days after the stroke, one may assume that the possible differences are not a result of immobilisation.
A large prospective study found that men with prevalent PAD had an increased rate of hip bone loss compared with men without PAD (-0.6% vs -0.3%, P < 0.001) [2] . In another, smaller, study the association between PAD and bone loss in women was weaker and not observed in men [15] . In addition, a number of cross-sectional studies showed that women and/or men with PAD have decreased BMD [19, [28] [29] [30] .
Numerous reports have looked at the association between subclinical atherosclerosis and osteoporosis. Men and women with progression of AC have significantly higher bone loss in the lumbar spine compared with subjects without AC progression (-1.5% vs 1.4%) [4] . This is in line with other studies where AC progression is associated with higher rates of bone loss in the proximal femur and metacarpal bones [1, 3] . Furthermore, several studies confirmed the prospective data and showed that subjects with calcifications in the aorta, coronary arteries, carotid arteries or femoral arteries have significant lower BMD compared with controls [31] [32] [33] [34] [35] [36] [37] [38] [39] . Only a few studies fail to find an association [40] [41] [42] [43] . In recent years, many studies have examined the association between atherosclerosis and osteoporosis. An increased IMT has been associated with severity of atherosclerosis and increased cardiovascular risk and considered useful in identifying subjects with increased risk [44] . An association between IMT and BMD was studied intensively and most of the studies reported an association of increased IMT with low bone density [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] . Endothelial dysfunction is considered to be an early phase of atherosclerosis and one way to measure this is to focus on arterial compliance. The endothelium plays an important role in determining vascular tone and dysfunction will result in increased arterial stiffness [55] . In line with earlier discussed results, an increased arterial stiffness is associated with low BMD [45, 54, [56] [57] [58] [59] [60] [61] .
Altogether, the results strongly suggest that subjects with subclinical atherosclerosis and early CV disease are at increased risk of bone loss. Again, there were insufficient data to reach conclusions about bone loss in patients with prevalent coronary or cerebral CV disease.
The relationship between osteoporosis and CV disease
Eighteen studies, most of moderate quality, reporting about the relationship between osteoporosis and CV disease were included. Results will be discussed per subcategory of CV disease, when possible. Low bone mineral density and cardiovascular mortality The association of osteoporosis with CV mortality was studied in 10 prospective studies [5, 7, 8, [62] [63] [64] [65] [66] [67] [68] (Table 2 ). Low bone mass was inversely related with CV mortality in seven studies [5, 7, 8, [62] [63] [64] 66, 67] .
Postmenopausal women with a low BMD had a 1.2-to 2.3-fold increased risk of dying from CV events, independent of traditional CV risk factors [7, 8, 66] . Similar results were found in elderly men [7, 67] . Studies in postmenopausal women with relative short follow-up periods (around three years) showed no or minimally significant elevated mortality rates [5, 63, 64] . Two large population-based studies in elderly men and women did not reveal a significant association between low bone mass and CV mortality [65, 69] . The most recent and largest study determined the risk of CV mortality in 5,272 persons [69] . Women with low BMD had higher risk for CV mortality; however, this did not reach significance (relative risk (RR) 1.26; 95% CI 0.88 to 1.80). No association was found in men.
Focusing on the few studies that reported the results per CV subcategory, women with low bone mass had no or a small increased risk for mortality by coronary heart disease (RR 1.17; 95% CI 0.92 to 1.51) and (relative hazard 1.3; 95% CI 1.0 to 1.8), respectively [5, 64] and two out of three studies showed that men and women with low BMD had a 1.3-to 1.7-fold increased risk for stroke mortality [5, 62, 65] . Low bone mineral density and incident cardiovascular disease A total of six studies assessed the risk of incident CV events in persons with osteoporosis [6, 62, [70] [71] [72] [73] . Most of them show a significant inverse relationship between BMD and incident CV events in women (HR 1.23 to 3.9) [6, 39, 62, 70] but not in men [6, 70] . Two studies related the prevalence of vertebral fractures with future CV events and were unable to find any association [68, 71] . Surprisingly, one study showed that women with prevalent fractures and known CHD had a reduced risk for CV events [73] .
Few articles assessed incident CV events separated per CV category. Three studies assessed the risk for CHD. Two studies showed an association with increased risk for CHD in postmenopausal women [72, 73] . One study could not find an association in elderly men and women [70] . Cerebrovascular events were studied in two articles. Both found an increased risk for stroke in postmenopausal women with low BMD with hazard ratios of 1.31 and 4.1 [62, 72] .
There was a considerable heterogeneity in measurement of osteoporosis. It is shown that the specificity and sensitivity of the densitometry tests differs greatly, and the site of measurement plays an important role in diagnosing osteoporosis as well [74] . Only six studies used dual energy absorptiometry (DXA) measurements to assess BMD [6, 64, 66, 67, 69, 75, 76] , while in the other studies BMD was measured with older techniques such as single photon absorptiometry, dual photon absorptiometry (DPA) or quantitative ultrasonography (QUS). Most studies measured BMD of the hip and lumbar spine, but also distal radius and heel were measured and in some the phalangeals. Low bone mineral density and subclinical atherosclerosis In addition to associations with CV events, low BMD has also been shown to be associated with surrogate markers of CV disease, such as vascular calcification. In women with the largest decrease in metacarpal cortical area during a 25-year follow-up, the most severe progression of aortic calcification was observed [77] and women with a prevalent vertebral fracture had a higher IMT measured 10 years later [75] . Moreover, results from several cross-sectional studies confirmed that both women and men with low bone mass, compared to subjects with normal bone mass, have significantly more subclinical atherosclerosis [20, 28, [31] [32] [33] [34] 37, 38, 45, 48, 49, 51, 52, 78, 79] , increased risk of peripheral arterial disease [28, 29, 34, 54] and other surrogate end markers for CV disease [57, 60, 61] .
Taken together, there is some evidence that persons with low BMD are at increased risk for CV events and subsequent CV mortality. However, variations in study design, for example, study population and outcome measures, limits interpretation. Since only a few studies assessed the CV outcome divided per CV subcategory, no conclusions can be drawn concerning a relationship between osteoporosis and specific categories of CV disease.
Links between CV disease and osteoporosis
Common pathogenesis
CV disease is preceded by atherosclerosis, for example, arterial disease. Atherosclerosis is a long-term process in which deposits of cholesterol, cellular waste products and calcium accumulates in the arterial wall causing it to thicken. Clinically, atherosclerosis is manifested by coronary heart disease, cerebrovascular disease and peripheral arterial disease. Endothelial dysfunction is the first step in the pathogenesis of atherosclerosis and predicts future CV events [80] . Calcification in the aorta and coronary arteries, for example, vascular calcification, may be a surrogate marker for atherosclerosis and increased CV risk [81] . In a recent meta-analysis patients with calcifications were found to have an increased risk for CV mortality and events [10] . Presently, vascular calcification is regarded as an active process, regulated by factors known to be involved in the process of osteogenesis, such as bone morphogenetic protein (BMP), alkaline phosphatase (ALP), osteopontin (OPN) and matrix GLA protein (MGP) [82] [83] [84] [85] (Figure 2 ). Accumulating evidence suggests that calcification is a consequence of active bone formation by osteoblast-like cells [86] . Vascular smooth muscle cells (VSMCs) are able to re-differentiate towards osteoblast-like cells and a subpopulation, that is, calcifying vascular cells (CVCs), were shown to form nodules and mineralisation spontaneously [87] . In vitro, these osteoblastic cells produce hydroxyapatite, a mineral important in bone formation [88] . In the following paragraphs some of the bone-related factors that are involved in vascular calcification will be discussed in more detail.
BMPs are members of the transforming growth factor-β superfamily and important factors in the regulation of osteoblast differentiation. BMP acts through upregulation of transcription factors important in bone metabolism, such as core binding factor-α1 (Cbfα1), also known as runt-related transcription factor 2 (Runx2), and msh homeobox 2 (Msx2). BMP appears to be an important mediator in vascular calcification. An increased expression of BMP2 and BMP4 is found in atherosclerotic lesions in endothelial cells, foam cells and VSMCs [88, 89] . In vitro studies showed that several factors that are known to induce CV disease, such as oxidative stress, oxidized low-density lipoprotein (ox-LDL) and tumor necrosis factor alpha (TNF-α), are able to upregulate BMP expression in endothelial cells [90, 91] .
MGP is a calcium-binding protein and requires vitamin K to function. MGP is found to be expressed in areas with arterial calcification [92] and may be an important calcification inhibitor. MGP knock-out mice developed extensive calcification in coronary arteries [93] . Recently the mechanism by which MGP inhibits calcification has become clear. In vitro, MGP has been shown to inhibit calcification by binding to BMP2, thereby blocking the induction of osteoblasts [94] .
OPN is a glycoprotein that accumulates in the extracellular matrix of bone tissue where it binds to hydroxyapatite and calcium. In bone, OPN is expressed by (pre-) osteoblasts and osteoclasts and is also found to be highly expressed in the atherosclerotic artery [89, 92] . Whether it promotes or inhibits calcification in the arterial wall is not completely clear [95] . While high OPN serum levels are associated with vascular calcification [96] and vitamin increases OPN and subsequent calcification in bovine VSMC's [97] , OPN is also shown to inhibit calcification by inhibiting de novo hydroxyapatite production [98] .
ALP is found on the surface of osteoblasts and is often used as a marker for bone turnover. ALP is an enzyme that catalyses the hydrolysis of phosphate esters. Hydrolysis of pyrophosphate, which is an inhibitor of hydroxyapatite formation, is especially needed to facilitate normal mineralisation [99] . In vitro studies in VSMC's showed that the ALP expression is increased in response to inflammatory markers, LDL and oxidative stress and this increased expression was associated with increased mineralisation [100] [101] [102] .
The recent identification of receptor activator of nuclear factor-kB (RANK), osteoprotegerin (OPG) and RANK ligand (RANKL) provides more insight into bone metabolism [103] . Most interestingly, there is increasing evidence that OPG is a key regulator in the pathogenesis of osteoporosis and vascular calcification. OPG production by osteoblastic cells is regulated by a number of factors, including BMP-2, inflammation, estrogen, vitamin D and oxidative stress [104] . OPG is expressed in various tissues, including the skeleton and vascular wall, and serves as a soluble decoy for RANKL [105] . Interestingly, OPG knock-out mice show, in addition to early-onset osteoporosis, increased vascular calcification [106] . In vitro studies have shown that OPG appears to be important for endothelial cell survival [107] and may inhibit active calcification [108] . Surprisingly, while experimental studies showed that OPG might protect against vascular calcification, OPG levels appear to be elevated in patients with CV disease. Several, but not all, clinical studies found a correlation of high OPG serum levels and more severe CV disease [45, 50, 62, [109] [110] [111] . Other pathways interacting with OPG might explain this discrepant finding. Estrogen deficiency results in an increased vascular OPG/RANKL ratio with subsequent increased calcification in an animal model [112] . Furthermore, pro-inflammatory cytokines are shown to elevate OPG levels in patients with CV disease [113] . Thus, while OPG appears to play a role in the pathogenesis of atherosclerosis, the exact mechanism remains to be elucidated.
Another important mechanism linking CV disease and osteoporosis is Wnt signalling, a combination of the genes Wg (wingless) and Int. Animal models showed the important role of Wnt signalling in bone formation through lipoprotein receptor-related protein 5 (LRP5), lipoprotein receptor-related protein 6 (LRP6) and β-catenin [114] . Wnt signalling is suggested to play an important role in bone formation and bone adaptation to mechanical loading [115, 116] . Interestingly, TNF-α [117] , oxidative stress [118] and vitamin D [119] are shown to promote vascular calcification through the Wnt signalling pathway and this supports the hypothesis that Wnt signalling is an interesting new molecular mechanism that influences bone and vascular metabolism.
Common risk factors
CV disease and osteoporosis are both common diseases in elderly men and women. While the increased prevalence of both conditions is often attributed to aging, most of the associations found in observational studies remain significant after adjustment for age. Other important traditional risk factors are also shared, such as inactivity, smoking, estrogen deficiency and chronic inflammation, explaining part of the link between CV disease and osteoporosis [9] .
Estrogen deficiency is considered an important risk factor for osteoporosis [120] and some studies suggest estrogen deficiency to be a cardiovascular risk factor [121] [122] [123] . Estrogen regulates bone turnover and the CV system directly and indirectly through the effects on the immune system, antioxidant system and other risk factors. After menopause, estrogen levels decrease rapidly resulting in an upregulated osteoclast formation and differentiation, inducing high bone turnover and accelerated bone loss [124] . Furthermore, following estrogen withdrawal the production and secretion of the proinflammatory cytokines interleukin-6 (IL-6), interleukin-1 and TNF-α is increased [116, 125] .
Presently, inflammation is considered to play an important role in the process of atherosclerosis [126, 127] . Both cellular and humoral pathways of the immune response contribute to an important part in the pathogenesis of atherosclerosis [128] . Markers of inflammation, such as pro-inflammatory cytokines and C-reactive protein (CRP), are involved in the development of atherosclerosis and CRP predicts cardiovascular events independently of other CV risk factors [129, 130] . There is accumulating evidence that inflammation influences bone metabolism and is considered to be the most important cause of postmenopausal osteoporosis. Proinflammatory cytokines enhance bone resorption directly through an induction of osteoclastogenesis or through the OPG pathway [116, 131] .
Recent research has identified new common mediators for vascular calcification and bone loss, such as hyperlipidemia, oxidative stress and vitamin D deficiency. An abnormal lipid profile, that is, high levels of total cholesterol, LDL and triglycerides and low levels of highdensity lipoprotein (HDL), is known to play a key role in development of atherosclerosis and CV disease [132, 133] . Interestingly, HDL is able to regulate the calcification of VSMCs [134] . HDL inhibited the spontaneous and cytokine induced osteogenic differentiation of CVCs in vitro. The role of lipids in the regulation of bone mass is more complicated. While experimental studies showed that ox-LDL influences bone metabolism [135] , results in observational studies are contradictory [1, [136] [137] [138] .
Oxidative stress is believed to increase with age and is associated with hypertension and atherosclerosis [139] . Free radicals have important effects on osteoclast differentiation and function [140] and oxidative stress markers are significantly associated with BMD [141] . In vitro, minimally oxidized low-density lipoprotein (MM-LDL) enhances the differentiation of VSMC's towards osteoblastic cells. Interestingly, antioxidants inhibited these effects [100] .
The prevalence of vitamin D deficiency is high among elderly men and women [142] and associated with osteoporosis and increased fracture risk [143] . Observational studies showed an inverse association of vitamin D deficiency with hypertension and CV events, suggesting a role for low vitamin D [144] [145] [146] [147] [148] . Proposed mechanisms are effects on myocardial gene expression, the renin-angiotensin axis or through secondary hyperparathyroidism. Important risk factors as physical condition and immobility were rarely assessed. Animal models and in vitro studies on the other hand, demonstrated that toxic levels of vitamin D induce vascular calcification [97, 149] . Interestingly, osteoprotegerin has been shown to inhibit the vitamin-induced calcifications in an animal model [150] . It has been suggested that vitamin D has a biphasic relation with vascular calcification and that both vitamin D deficiency and vitamin D excess results in increased vascular calcification.
Genetic studies
In complex, multifactorial diseases genetic factors are believed to play an important role in the pathogenesis in addition to environmental influences. Identifying candidate genes offers opportunities to gain more insight into possible shared pathogenesis and common risk factors in CV disease and osteoporosis. Many candidate genes have been examined, mainly genes coding for known factors, such as cytokines, bone-associated factors and receptors. The genes that might be involved in both diseases will be discussed here.
Polymorphism in the IL-6 gene, a cytokine involved in bone metabolism and CV disease, might be an interestingly candidate gene. A G174C polymorphism in the promoter region of the IL-6 gene was shown to be associated with low bone mass in the radius in postmenopausal women [151] and with a high blood pressure and increased CV risk in men [152] .
Vitamin D receptor polymorphisms have been associated in many studies with bone density [153, 154] . Although this could not be replicated in a large metaanalysis, it did show that the Cdx2 polymorphism was associated with risk for vertebral fractures [155] . In addition, the BsmI polymorphism was associated with IMT and myocardial infarction (MI) [156, 157] , strengthening the possible role of vitamin D in linking CV disease and osteoporosis.
One of the most interesting candidate genes to mention is the OPG gene, located on chromosome 8 and several single nucleotide polymorphisms (SNPs) are identified in this gene. So far, studies were able to associate different SNPs with either bone density or vascular disease. SNPs A163G and T245G were associated with osteoporotic fractures [158] . The linked polymorphisms T950C and C1181C within the promoter region of the OPG gene were associated with an increased risk for CAD in men [159] . In addition, C1181C was also associated with first-ever intracerebral haemorrhage [160] . Furthermore, another SNP in the promoter region in the TATA box was related to vascular morphology and function [161] .
A genetic defect in the Wnt signalling pathway was recently discovered in a family with features of metabolic syndrome and early onset coronary artery disease [162] . This rare mutation in the LRP6 gene is associated with dyslipidemia, hypertension and diabetes. This finding supports further research for mutations in genes involved in the Wnt signalling pathway.
Collagen type I is an important protein in the mineralisation matrix and connective tissue. Mutations in this gene are associated with low BMD and fracture risk [163] . Interestingly, besides low BMD, individuals with a SNP in the COL1A gene (rs42524) had an increased prevalence of stroke and MI [164] .
The calcium-sensing receptor (CASR) is a receptor involved in the regulation of calcium homeostasis. A SNP in the CARS gene (A986S) was associated with higher serum calcium and increased prevalence of coronary artery disease (CAD) and MI [165] . This SNP was also associated with low BMD in premenopausal women [166] . However, the role in postmenopausal osteoporosis is not clear, since several studies showed no association of this SNP with BMD or fracture risk in postmenopausal women [167, 168] .
An interesting candidate gene to mention is the klotho gene. Defects in the klotho gene have been shown to result in arteriosclerosis and increased IMT in klotho deficient mice [169] . A SNP in this gene (G395A) was associated with CAD. Surprisingly, this same SNP was associated with bone density [170] and was suggested to be involved in the pathophysiology of bone loss. This SNP in the promoter region resulted in impaired function of the gene. What makes this gene interesting is that it might offer a new treatment approach, because the abnormalities seen in klotho-deficient mice can be reversed by restoring the klotho expression [171] .
Finally, polymorphisms in the apolipoprotein E (APOE) gene has been studied intensively. It has been associated with hypertension, atherosclerotic disease and CV disease [172] [173] [174] . Furthermore, APOE gene polymorphisms have been suggested to be associated with low BMD and fracture risk. However, a recent metaanalysis was unable to show a strong and consistent association with BMD and fracture incidence [175] .
Discussion
Our study is the first to systematically review the epidemiological literature about the association between CV disease and osteoporosis. An extensive literature search yielded 27 prospective studies addressing this relationship. Due to considerable heterogeneity in study design and outcome measurements the results could not be pooled. Focusing on the methodologically strongest studies (those with minimal selection bias and the appropriate assessments, that is, a methodological score of more than 3), our review indicates that the prevalent subclinical CV disease predicts future fractures and bone loss [2] [3] [4] [13] [14] [15] (Table 4) .
Furthermore, there is some evidence that low bone mass predicts CV mortality and CV events [6, 62, 68, 69, 75] .
Interestingly, several studies demonstrated shared risk factors, supporting the existence of a direct association between vascular calcification and bone biology.
Due to the substantial diversity of patients and study methods, pooled analysis was not considered appropriate. Although numerous efforts were made to investigate the association between CV disease and osteoporosis, a vast majority of studies used secondary outcome measurements, while a limited number of studies used primary outcome measurements such as incident CV events or osteoporosis. Furthermore, the population studied varied with respect to age, sex, baseline risk for CV events or fractures and ethnicity. Larger prospective studies in elderly persons, men and women, are needed to answer this question. To reduce heterogeneity we encourage that in new studies well-defined outcome Table 4 Summary of findings in high quality prospective studies measures should be incorporated, such as incident CV disease presented per subcategory of CV disease and measurement of BMD by DXA-scans on regular interval periods.
Conclusions
The current evidence indicates that individuals with prevalent (sub)clinical CV disease are at increased risk for bone loss and subsequent fractures. Presently, no firm conclusions can be drawn to which extent low BMD might be associated with increased cardiovascular risk. Age, estrogen deficiency and inflammation represent the most important common risk factors and the discovery of new pathways, for example, OGP/RANKL and Wnt signalling, might provide interesting new therapeutic options. Altogether our results suggest that bone density screening could be recommended in patients with prevalent CV disease. 
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